Microrchidia 2 (MORC2) is important in DNA damage repair and lipogenesis, however, the clinical and functional role of MORC2 in liver cancer remains to be fully elucidated. The aim of the present study was to clarify the role of MORC2 in liver cancer. Expression profile analysis, immunohistochemical staining, reverse transcription-quantitative polymerase chain reaction analysis and western blot analysis were performed to evaluate the levels of MORC2 in liver cancer patient specimens and cell lines; subsequently the expression of MORC2 was suppressed or increased in liver cancer cells and the effects of MORC2 in the cancerous transformation of liver cancer cells were examined in vitro and in vivo. MORC2 was upregulated in liver cancer tissues, and the upregulation was associated with certain clinicopathologic features of patients with liver cancer. MORC2 knockdown caused marked inhibition of liver cancer cell proliferation and clonogenicity, whereas increased migration and invasion rates were observed in cells with ectopic expression of MORC2. In addition, the knockdown of MORC2 inhibited the migratory and invasive ability of liver cancer cells, whereas increased migration and invasion rates were observed in cells with ectopic expression of MORC2. In a model of nude mice, the overexpression of MORC2 promoted tumorigenicity and markedly enhanced pulmonary metastasis of liver cancer. Furthermore, MORC2 regulated apoptosis and its expression level had an effect on the sensitivity of liver cancer cells to doxorubicin, 5-fluorouracil and cisplatin. Mechanically, MORC2 modulated the mitochondrial apoptotic pathway, possibly in a p53-dependent manner, and its dysregulation also resulted in the abnormal activation of the Hippo pathway. For the first time, to the best of our knowledge, the present study confirmed that MORC2 was a novel oncogene in liver cancer. These results provide useful insight into the mechanism underlying the tumorigenesis and progression of liver cancer, and offers clues into potential novel liver cancer therapies.

Introduction
Liver cancer is a prevalent malignancy worldwide and ranks as one of the leading causes of cancer-associated mortality (1). The mechanism of liver cancer is complicated and heterogeneous, and is accompanied by various molecular abnormalities. It is necessary to identify novel oncogenes and tumor suppressors for further investigation and potential clinical application.

The microrchidia (MORC) family proteins are conserved proteins with important roles in multiple biological processes. MORC2, also known as ZCWCC1, ZCW3, KIAA0852 and AC004542.C22.1, is a member of this family (2,3). It contains an ATPase domain, a zinc finger type CW domain, and nuclear localization signal and coiled-coil domains (2-4). It has been reported that MORC2 can bind with histone deacetylase (HDAC)4 and functions as a transcriptional repressor by mediating the deacetylation of histone H3 (5). A limited number of studies have shown that MORC2 can bind with histone deacetylase (HDAC)4 and functions as a transcriptional repressor by mediating the deacetylation of histone H3 (5). A limited number of studies have shown that MORC2 can bind with histone deacetylase (HDAC)4 and functions as a transcriptional repressor by mediating the deacetylation of histone H3 (5).

MORC2 can promote the migration and invasion of breast cancer cells, and is involved in a prognostic prediction model for breast cancer. Furthermore, MORC2 regulated apoptosis and its expression level had an effect on the sensitivity of liver cancer cells to doxorubicin, 5-fluorouracil and cisplatin. Mechanically, MORC2 modulated the mitochondrial apoptotic pathway, possibly in a p53-dependent manner, and its dysregulation also resulted in the abnormal activation of the Hippo pathway. For the first time, to the best of our knowledge, the present study confirmed that MORC2 was a novel oncogene in liver cancer. These results provide useful insight into the mechanism underlying the tumorigenesis and progression of liver cancer, and offers clues into potential novel liver cancer therapies.
cancer containing six genes (8,9). Its oncogenic role in gastric cancer has also been demonstrated (10-12). For example, it has been reported that MORC2 downregulates p21 by recruiting HDAC1 to the p21 promoter, in a p53-independent manner in gastric cancer; the phosphorylation of MORC2 increases the expression of cyclin D1-cyclin-dependent kinase (CDK)4 and cyclin D3-CDK6 complexes, promotes gastric cell cycle transition from the G1 to S stage, and indicates a poorer prognosis in patients with gastric cancer (11,12).

However, to date, no studies have reported on the clinicopathologic significance and functions of MORC2 in liver cancer. The present study presented the first evidence, to the best of our knowledge, of the expression pattern of MORC2 in human liver cancer and its clinical significance. The roles of MORC2 in the progression of liver cancer and its underlying mechanisms were investigated. The data demonstrated that MORC2 was upregulated in liver cancer, and contributed to the proliferation, metastasis and chemoresistance of liver cancer cells via the p53 and Hippo pathways.

Materials and methods

Cell culture, culture conditions and antibodies. The HepG2, Bel-7402, Huh7, PLC/PRF-5, SMMC7721 and LM3 liver cancer cell lines were obtained from the Cell Bank of the Chinese Academy of Sciences Committee Type Culture Collection (Shanghai, China), and the normal LO2 liver cell line was conserved at the Central Laboratory of Renmin Hospital of Wuhan University (Wuhan, China). The cells were cultured in DMEM supplemented with 10% fetal bovine serum (FBS) (Zhejiang Tianhang Biotechnology Co., Ltd., Hangzhou, China) and 100 units penicillin/streptomycin. The cells were cultured at 37˚C and 5% CO2 in a humidified chamber. Rabbit monoclonal anti-MORC2 antibody was purchased from Abcam (Cambridge, UK). Mouse monoclonal anti-β-actin antibody was purchased from Santa Cruz Biotechnology, Inc. (Dallas, TX, USA). Anti-rabbit and anti-mouse horseradish peroxidase (HRP)-conjugated secondary antibodies were purchased from Promega Corporation (Madison, WI, USA).

Patients and histological and immunohistochemical (IHC) staining. The GSE14520 and GSE22058 mRNA expression profile were downloaded from the Gene Expression Omnibus (GEO) database (13-15). The Cancer Genome Atlas (TCGA) copy number-altered genome data for each patient was directly downloaded from cBioPortal for Cancer Genomics (16,17). All liver cancer samples and paired adjacent tissues were downloaded from the Cancer Genome Atlas (TCGA) as shown in Table I. The cells were transfected with 50 ng/µl targeting siRNA using Lipofectamine 2000 (Invitrogen; Thermo Fisher Scientific, Inc., Waltham, MA, USA) for 48 h, following which the depletion efficiency was analyzed by western blot analysis. siRNA-homo-1760 was selected for the following experiments, as it exhibited the optimal efficiency. For the establishment of stable MORC2-overexpressing cells, the overexpression plasmid was constructed using the pLV-EGFP (2A) puro plasmid; the plasmid was packed using a lentivirus system (both from Inovogen Biotechnology Co., Ltd., Beijing, China). Following infection, the cells were selected for 4 weeks using DMEM with 10 µg/ml puromycin (Sigma-Aldrich; Merck KGaA, Darmstadt, Germany). The expression of MORC2 was lowest in the PLC cell line, however, the overexpression efficiency was not satisfactory in this cell line, thus the SMMC7721 cell line was used to construct the stable MORC2-overexpressing cells in the present study.

Western blot analysis. In brief, cells were lysed in lysis buffer containing 50 mmol/l Tris (pH 8.0), 150 mmol/l NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, 50 mmol/l NaF, 1 mmol/l Na3VO4. Protein concentration was analyzed and adjusted using a bicinchoninic acid protein assay. Subsequently, equal quantities (50 µg) of samples were separated by 10% SDS-PAGE (Bio-Rad Laboratories, Inc., Hercules, CA, USA) and transferred onto nitrocellulose membranes (EMD Millipore, Billerica, MA, USA). After blocking with 5% non-fat milk in Tris-buffered saline containing 0.05% Tween-20, the membranes were incubated with primary antibodies against MORC2 (1:400, bs-0354R; BIOSS, Beijing, China), cytochrome c (1:200, ab53056), caspase-3 (1:500, ab47131) (both from Abcam), caspase-9 (1:150, sc-56076; Santa Cruz Biotechnology, Inc.), poly (ADP-ribose) polymerase (PARP) (1:150, ab4830; Abcam), p53 (1:500, sc-6243), B-cell lymphoma-2 (Bel-2) (1:500, sc-783), Bel-2-associated X protein (Bax) (1:300, sc-493) (all from Santa Cruz Biotechnology, Inc.), p53 upregulated...
Table I. siRNA sequences used for the overexpression of MORC2.

| siRNA | Sense (5'-3') | Antisense (5'-3') |
|-------|---------------|------------------|
| MORC2-homo-1760 | GCCGAACAUUGUGGUAUCAUTT | AUGAUCCAAUAUGUUCGGCTT |
| MORC2-homo-2439 | GAGGCCUACACACACAATAATT | UUGUUGUGUGUAGGCUCCCTT |
| MORC2-homo-3972 | GCAGCUGAGUGCUAGUAUATT | AUCUAGACACUCACAGCGCTT |
| Control siRNA | UUCUGCAACGUGUCACGUTT | ACGUGACACUGCCGAATT |

siRNA, small interfering RNA; MORC2, microchordia 2.

Table II. Primers used for human MORC2 and β-actin.

| Primer | Sequence (5'-3') |
|--------|------------------|
| Homo-MORC2-F | GAAAGCCTGCCAACACTCTC |
| Homo-MORC2-R | TCTACAGAAACTGCGACA |
| Homo-β-actin-F | CATTAAGGGAAGCTGTGCT |
| Homo-β-actin-R | GTTGAAGGTAGTTTCGTGGA |

MORC2, microchordia 2; F: forward; R: reverse.

modulator of apoptosis (PUMAγ) (1:5000, ab33906; Abcam), Yes-associated protein 1 (YAP1) (1:500, orb89757; Biortyt Ltd., Cambridge, UK), phosphorylated (p-)S127-YAP1 (1:10,000, ab76252; Abcam), Transcriptional co-activator with PDZ-binding motif (TAZ) (1:500, #23306-1-AP; ProteinTech Group, Inc., Chicago, IL, USA), p-S89-TAZ (1:500, sc-17610), and β-actin (1:1,000, sc-47778) (both from Santa Cruz Biotechnology, Inc.) at 4˚C overnight. The primary antibodies coupled to sample proteins were then visualized by incubation for 1 h at 37˚C with HRP-conjugated secondary antibodies (1:10,000, 074-1506 and 074-1806; KPL, Inc., Gaithersburg, MD, USA) using a chemiluminescence detection system (EMD Millipore) according to the manufacturer’s protocol.

Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) analysis. Total RNA from the tissues and cells was isolated using TRIzol (Invitrogen; Thermo Fisher Scientific, Inc.). Subsequently, 2 µg of total RNA from each sample was used for cDNA synthesis. RT-qPCR analysis was performed in triplicate with the SYBR® Green PCR Master mix (Takara Bio, Inc., Otsu, Japan) and β-actin was used as an internal control according to the manufacturer’s protocol. Each sample included: 4 µl cDNA, 2 µl primers, 12.5 µl 2X SYBR Green master mix and 6.5 µl ddH2O. The PCR thermocycling conditions were as follows: 5 min at 94˚C, followed by 40 cycles at 94˚C for 20 sec, 60˚C for 20 sec and at 72˚C for 20 sec, and 5 min at 72˚C. Relative expression levels of target genes were determined according to the 2ΔΔCq method (18), where Cq represents the quantification cycle for each transcript. The primer pairs for human MORC2 and β-actin were designed as shown in Table II.

Cell counting kit-8 (CCK-8) assay. In the cell proliferation assay, the cells (1x10^5/well) were plated onto 96-well plates on the first day and allowed to attach overnight. The following day, 10 µl of CCK-8 (Dojindo Molecular Technologies, Inc., Kumamoto, Japan) was added to each well and incubated at 37˚C and 5% CO₂ for 1 h between days 1 and 5. The absorbance was then detected with the multifunctional microplate reader at 490 nm. For the chemoresistance assay, following seeding of the cells (1x10^5/well) in the plates, the cells were treated with the chemotherapeutics, doxorubicin, 5-fluorouracil and cisplatin, at different concentrations (0, 1, 5, 10, 20, 40, 80 and 100 µM) for 72 h at 37˚C, following which CCK-8 was added. Following incubation at 37˚C and 5% CO₂ for 1 h, the absorbance was detected and the half maximal inhibitory concentration (IC₅₀) parameter was calculated.

Plate colony formation assay. The cells were digested with trypsin, centrifuged at 110 x g for 5 min at 37˚C, resuspended in DMEM supplemented with 10% FBS and seeded in 6-well plates (1,000 cells/well), following which the cells in each group were cultured for 2 weeks. The cells were then washed twice with PBS, fixed with 4% paraformaldehyde for 20 min, and then stained with 0.1% crystal violet for 30 min. The dishes were then carefully washed with PBS until the background was clear. Finally, the number of colonies was counted under a microscope (CKX41; Olympus Corporation).

Cell-cycle analysis. In brief, the cells were digested with trypsin, centrifuged at 110 x g for 5 min at 37˚C, resuspended in PBS, washed twice with PBS and then fixed in 100% ice-cold methanol overnight at -20˚C. The cells were then incubated with 50 mg/ml propidium iodide (PI) and 1 mg/ml RNAase in PBS for 20 min, following which the samples were analyzed with BD FACSAria (BD Biosciences, Franklin Lakes, NJ, USA).

In vitro migration and invasion assays. In the scratch wound healing assay, cells were cultured in serum-free medium for 24 h and wounded with pipette tips. Subsequently, the medium was replaced with fresh medium. The wound healing procedure was observed after 48 h, and images of the cells were captured under a microscope (CKX41; Olympus Corporation). Cell migration and invasion assays were performed using Transwell chambers, as previously described (19). The cells were harvested and resuspended in serum-free medium, and then added to the upper chamber. Following incubation for 48 h, cells remaining on the upper side of membrane were removed with a cotton swab. The cells migrated to the lower membrane surface were fixed and stained with 0.1% crystal violet for 30 min, and the number of cells was counted under a microscope. To assess invasion ability, the membranes were
pre-coated with diluted Matrigel, whereas the membranes in migration experiments were not pre-coated with Matrigel.

**Nude mice experiments.** All animal experiments were approved by the Ethics Review Board of the Second People's Hospital of Guangdong Province (approval no. 2015-KYLL-063). For the experiments, 4-week-old male BALB/C nude mice (Hangzhou Hibio Technology Co., Ltd., Hangzhou, China) were used. The mice were maintained under the following pathogen-free conditions: 60% humidity; room temperature; 12-h light/dark cycle; *ad libitum* access to food and water. In a subcutaneous xenograft procedure, 1x10^6 cells (SMMC7721MORC2 or SMMC7721Vector) were resuspended in PBS solution and then injected subcutaneously into the left and right side of each of the mice (n=6). The tumor size was measured every 3 days, and tumor volume was calculated using the following formula: 1/2 length x width^2. For the assessment of pulmonary metastasis, 10 mice were included in each group, and 1x10^6 cells (SMMC7721MORC2 or SMMC7721Vector) were injected into the caudal vena. After 2 weeks, the mice were sacrificed and lung colonization was quantified by pathological examination.

**Analysis of apoptosis.** Annexin V-FITC/PI staining was used to investigate whether MORC2 regulates the apoptosis of liver cancer cells. The cells were seeded into 6-well plates. When the cells in each group were at a log phase of growth, the cells were digested with trypsin, centrifuged at 110 x g for 5 min at 37°C and resuspended in PBS. The cells were then incubated with an ApoScreen Annexin V Apoptosis kit and PI. Every sample containing 10,000 cells was analyzed using BD FACSAria (BD Biosciences). The experiments were performed in triplicate.

**Statistical analysis.** Statistical significances between values of different experimental groups were analyzed using Student’s t-test or one-way analysis of variance. A χ^2 test and Fisher's test were used in analyzing enumeration data and pathway analysis. P<0.05 was considered to indicate a statistically significant difference. All statistical analyses were conducted using GraphPad Prism 6.0 (GraphPad Software, Inc., La Jolla, CA, USA) or SPSS for Windows 17.0.1 software (SPSS, Inc., Chicago, IL, USA). Expression profile analysis was conducted on L02MORC2 and L02Vector data (Chen et al., unpublished data) using GCBI 1.0 software (Gminix Technology Co., Ltd., Shanghai, China) with the Kyoto Encyclopedia of Genes and Genomes database (http://www.genome.jp/kegg/) as reference.

**Results**

**MORC2 is overexpressed in liver cancer samples at the mRNA and protein levels.** By analyzing the expression profile of liver cancer samples from GEO datasets GSE14520 and GSE22058, it was found that the mRNA levels of MORC2 were significantly upregulated in the liver cancer tissues, compared with the matched non-tumorous tissues (Fig. 1). The expression levels of MORC2 in 73 liver cancer and corresponding adjacent liver tissues specimens were then examined using IHC staining. Consistent with previous reports, MORC2 was expressed mainly in the nucleus and was relatively weak in the cytoplasm (Fig. 2). The results showed that MORC2 was overexpressed in the majority (72.6%, 53/73) of the liver cancer samples (Fig. 2). RT-qPCR analysis was also used to examine the levels of MORC2 in 10 pairs of liver cancer and pair-adjacent liver tissue specimens; accordingly, the expression of MORC2 was upregulated in almost all the cancerous tissues (Fig. 3A). The expression level of MORC2 was then examined in HepG2, Bel-7402, Huh7, PLC/PRF-5, SMMC7721, LM3 and L02 cells. Higher expression of MORC2 was observed in the majority of the liver cancer cells, compared with the L02 cells (Fig. 3B). From these results, it was concluded that MORC2 was overexpressed in liver cancer at the mRNA and protein level, demonstrating the important role of MORC2 in the pathogenesis of liver cancer.

**High expression of MORC2 leads to accumulation of copy number variations and unfavorable pathological characteristics.** Dysfunctional DNA damage repair results in genetic alterations, including somatic copy number alteration, and this characteristic is increasingly recognized as common feature of human liver cancer (20). It has been reported that MORC2 is associated with chromatin remodeling, promotes the induction of γ-H2AX and modulates DNA damage repair (6). Utilizing the data of TCGA database (16,17), it was detected that the fraction of copy number alterations was higher in the genome of patients with liver cancer and higher MORC2 (Fig. 4). This result indicated that the upregulation of MORC2 may result in liver cancer progression via accumulating extra copies of DNA.

Using the clinical information of GSE14520, the correlation between the expression of MORC2 and clinicopathological features was assessed to determine its clinical significance. The samples were divided into two groups according to the expression level and were analyzed with χ^2 test. As shown in Table III, a higher expression of MORC2 was associated with larger tumor volume (P=0.009) and higher American Joint Committee on Cancer T stage (P=0.007). These results indicated that MORC2 may be a potential prognostic biomarker in liver cancer.

In liver cancer cells, knockdown of MORC2 inhibits proliferation in vitro. Gene set enrichment analysis (GSEA) was performed in order to identify potential genes modulated by MORC2. The mRNA expression profiling data in GSE14520 were used to outline MORC2-correlated genes. In the GSEA analysis of Gene Ontology terms, it showed that gene sets involved in ‘cell cycle process’ and ‘mitosis’ were enriched in the MORC2-high expression samples (Fig. 5). Enhanced mitogenic signaling and aberrant process of cell cycle are essential for cell proliferation and cancer progression (20). The bioinformatics data provided a possible explanation of why a high expression of MORC2 was associated with unfavorable clinicopathological features, including tumor size and T stage (Table III). The results suggested that MORC2 has an important function in the proliferation of liver cancer cells.

To verify the biological role of MORC2 in the proliferation of liver cancer, MORC2 was knocked down using siRNAs in HepG2, Bel-7402 and LM3 cells, which had a higher expression of MORC2. Western blot analysis was used to determine the knockdown efficiency (Fig. 6A).
The effect of MORC2 on cell proliferation was then examined. As shown in Fig. 6B, compared with the control groups, following MORC2 knockdown, the HepG2, Bel-7402 and LM3 cells exhibited a significantly lower cell proliferation rate (Fig. 6B). Furthermore, cell proliferation was measured using a plate colony formation assay. Compared with the control cells, MORC2 knockdown in the HepG2, Bel-7402 and LM3 cells resulted in markedly decreased colony formation abilities (Fig. 6C).
In liver cancer cells, inhibition of MORC2 promotes cell cycle arrest and induces apoptosis. Enhanced cell cycle progression and reduced apoptotic signaling are two important factors causing sustained proliferation. To examine the factors involved in MORC2 regulating the proliferation of liver cancer cells, the cell cycle was detected in liver cancer cells through flow cytometry. Following transfection with si-MORC2 or si-NC for 48 h, the inhibition of MORC2 led to a significant accumulation of cells at the G0/G1-phase and a marked decrease in cells at the S/G2/M-phase in HepG2, Bel-7402 and LM3 cells (Fig. 7A). Subsequently, the effects of MORC2 on apoptosis under normal condition or oxidative stress (treated with H2O2) were investigated. The knockdown of MORC2 markedly increased apoptosis of the HepG2 cells (Fig. 7B). These results indicated that the downregulation of MORC2 promoted cell cycle arrest and induced the apoptosis of liver cancer cells.

Knockdown of MORC2 inhibits cell migration and invasion of liver cancer cells in vitro. The clinicopathological analysis also revealed that a higher expression level of MORC2 was significantly associated with a gene expression signature of higher metastatic potential (P<0.001, Table III), however, the role of MORC2 in cancer cell metastasis has not been investigated previously. Cell migration and invasion are critical during the multistep process of cancer cell metastasis. The present study assessed whether MORC2 was a crucial molecule involved in cell migration and invasion using Transwell assays. MORC2-loss of function inhibited the migration and invasion rates of the HepG2, Bel-7402 and LM3 cells (Fig. 7A). Subsequently, the effects of MORC2 on apoptosis under normal condition or oxidative stress (treated with H2O2) were investigated. The knockdown of MORC2 markedly increased apoptosis of the HepG2 cells (Fig. 7B). These results indicated that the downregulation of MORC2 promoted cell cycle arrest and induced the apoptosis of liver cancer cells.

Overexpression of MORC2 promotes the malignant phenotypes of the SMMC7721 liver cancer cell line in vitro and in vivo. The SMMC7721 cell line, which had a relatively lower expression of MORC2, was used to construct cells overexpressing MORC2 using a lentivirus-mediated packed pLV-MORC2 vector. Western blot analysis was used to determine the knockdown and
ectopic expression (Fig. 9A). Compared with the control group, SMMC7721 cells exhibited a significantly higher cell viability rate when MORC2 was overexpressed (Fig. 9B). Similarly, the MORC2-overexpressing SMMC7721 cells exhibited significantly increased colony formation (Fig. 9C). The overexpression of MORC2 increased the cell cycle progression and decreased the number of apoptotic cells (Fig. 9D and E). Furthermore, SMMC-7721 cells stably expressing MORC2 exhibited enhanced migration, invasion and movement, compared with the control cells (Fig. 10). The in vivo experiments showed that the overexpression of MORC2 significantly increased tumor volume in a subcutaneous xenograft model (Fig. 11A). Colonization at a distant site is the last key step in the metastatic cascade (21). The present study also used a tail vein injection model to imitate the pathophysiological process to determine whether MORC2 was involved in the distant colonization of liver cancer cells. At 2 weeks post-injection, the mice were sacrificed by cervical dislocation, and lung colonization was quantified by pathological examination. In line with the observation in vitro, all 10 mice exhibited severe lung metastasis in the MORC2-overexpression group, the incidence of which was significantly higher, compared that in the empty vector group (1/10; P<0.001) (Fig. 11B and C). These results revealed the promoting role of MORC2 in liver cancer metastasis.

Figure 5. GSEA results indicate that MORC2 modulates the proliferation of liver cancer cells. GSEA analysis of Gene Ontology terms showed MORC2 may regulate gene sets associated with cell cycle checkpoint (left), cell cycle progress (middle) and mitosis (right). GSEA, gene set enrichment analysis; MORC2, microorchidia 2.

Figure 6. MORC2 modulates proliferation of liver cancer cells in vitro. (A) Knockdown of MORC2 in HepG2 (left), Bel-7402 (middle) and LM3 (right) cell lines by siRNA targeting MORC2 was confirmed by western blot analysis; β-actin was used as a loading control. (B) Effect of MORC2-knockdown on the proliferation of HepG2 (left), Bel-7402 (middle) and LM3 (right) cells was determined using a cell counting kit-8 assay. (C) Effect of MORC2-knockdown on colony numbers was determined using a colony formation assay in HepG2 (left), Bel-7402 (middle) and LM3 (right) cells. *P<0.05; **P<0.01; ***P<0.001. MORC2, microorchidia 2; siRNA, small interfering RNA; CON, control; KD, knockdown; NC, negative control.
Inhibition of MORC2 improves the sensitivity of liver cancer cells to chemotherapeutic drugs. The present study also examined whether MORC2 has the potential to be applied in clinical liver cancer treatment. Chemotherapy provides an optional strategy in the treatment of liver cancer, particularly for patients with advanced tumors. However, chemotherapy is unsatisfactory due to chemoresistance (22). The present study hypothesized that the negative effect of MORC2 on the apoptosis of liver cancer cells may also contribute to the drug resistance of liver cancer cells. To test this hypothesis, chemosensitivity to the three most common chemotherapeutic drugs, doxorubicin, cisplatin and 5-fluorouracil, was assayed in MORC2-knockdown groups and control groups. The results showed that the IC50 values of all the chemotherapeutic drugs were significantly decreased by the knockdown of MORC2 (Table IV). Therefore, MORC2 contributed to enhancing the chemotherapeutic sensitivity of liver cancer cells.

To determine the mechanisms by which MORC2 affects apoptosis and chemoresistance, the expression levels of apoptosis-related proteins were examined following the knockdown of MORC2 in the cells. As shown in Fig. 12A, in the HepG2, Bel-7402 and LM3 cells, si-MORC2 transfection induced the cleavage of caspase-9, caspase-3 and PARP, and the release of mitochondrial cytochrome c into the cytosol. These results demonstrated that MORC2 affected apoptosis and chemoresistance by modulating the mitochondrial apoptotic pathway.

Dysregulation of MORC2 disrupts p53 and Hippo pathways. The p53 tumor-suppressor gene regulates apoptosis through...
the transcriptional activation of its target genes, and the mitochondrial apoptotic pathway is regulated by several p53-target genes, including Bax, Bcl-2, p53AIP1, Noxa and Puma (23-25). Therefore, the present study examined the possible association between p53 and MORC2 in liver cancer. By comparing the expression profile of L02\textsuperscript{MORC2} and L02\textsuperscript{Vector}, we found that the overexpression of MORC2 significantly enriched genes involved in the p53 pathway (P<0.001) (Fig. 12B), which was consistent with our hypothesis. To confirm this result, the effect of MORC2-knockdown on the expression level of p53 and its target genes, including Bax, Bcl-2 and PUMA\textsuperscript{α}, were examined. It was found that the knockdown of MORC2 increased the expression of p53, Bax and PUMA\textsuperscript{α}, and reduced the expression of Bcl-2, compared with the control (Fig. 12C). The overexpression of MORC2 also notably enriched genes involved in the Hippo pathway (Fig. 12B). Further validating these results, the results of the western blot analysis showed that MORC2-knockdown increased phosphorylated Yes-associated protein (YAP) and TAZ (Fig. 12D). These results suggested that MORC2 may promote Hippo pathway activation in tumorigenesis. Collectively, the dysregulation of MORC2 in liver cancer disrupted the p53 and Hippo pathways during cancer progression.

**Discussion**

The DNA damage response (DDR), is associated with oncogenesis (26,27). The dysregulation of DNA damage repair-related genes results in the genomic instability, promoting the accumulation of DNA mutations and chromosomal aberrations.
Increasing evidence indicates that a high expression of certain DDR-related genes is crucial in causing chemoresistance, which eventually results in unsatisfactory treatment in cancer patients (28-31). It has been reported that p21 protein (Cdc42/Rac)-activated kinase 1 phosphorylation of MORC2 on serine 739 modulates ATPase-dependent chromatin remodeling following double-strand break damage, and facilitates efficient DNA damage repair (6). On finding that MORC2 was upregulated in liver cancer tissue, it was hypothesized that liver cancer cells with high expression levels of MORC2 are able to elicit more effective homologous recombination DNA repair, and may be less sensitive to apoptotic signals, leading to aberrant cell cycle progression, and higher survival ability and chemoresistance. Accordingly, in patients with liver cancer, the present study found that a higher fraction of copy number alterations in the genome was detected with higher expression of MORC2. It was also found that MORC2-knockdown induced cell cycle arrest and endogenous apoptotic pathways. The knockdown of MORC2 also sensitized liver cancer cells to doxorubicin, 5-fluorouracil and cisplatin, and markedly increased IC50.

Table IV. siRNA-mediated knockdown of MORC2 increases the sensitivity of liver cancer cells to chemotherapeutics.

| Cell group | IC50 values |       |       |       |
|------------|-------------|-------|-------|-------|
|            | Doxorubicin (µM) | Cisplatin (µM) | 5-fluorouracil (µM) |       |
| HepG2      |             |       |       |       |
| si-NC      | 33.53       | 25.88 | 42.82 |       |
| si-MORC2   | 8.86        | 7.89  | 14.04 |       |
| Bel-7402   |             |       |       |       |
| si-NC      | 34.24       | 39.78 | 50.54 |       |
| si-MORC2   | 15.27       | 27.84 | 31.12 |       |
| LM3        |             |       |       |       |
| si-NC      | 29.72       | 43.23 | 23.68 |       |
| si-MORC2   | 19.89       | 35.77 | 12.06 |       |

MORC2, microrchidia 2; si, small interfering RNA; NC, negative control; IC50, half maximal inhibitory concentration.
values, which suggested that MORC2 may be involved in the chemoresistance of liver cancer.

The p53 and Hippo pathways are two crucial pathways in cancer progression. p53 has been investigated intensively as...
a major tumor suppressor (23-25), p53 can be activated and transcriptionally induces several target genes in response to various stress signals. Its downstream genes include modulators controlling cell proliferation, apoptosis, DNA repair, autophagy, migration and metabolism (23). In the majority of types of human cancer, p53 is inactivated or missing through multiple mechanisms, resulting in tumorigenesis, cancer progression and metastasis (23-25). It has been demonstrated that the Hippo signaling pathway is pivotal in the regulation of tissue and organ size during development (32). The dysregulation of Hippo signaling leads to the inhibition of apoptosis and uncontrolled cellular proliferation (32,33). Despite diverse upstream mechanisms that regulate the Hippo pathway in cancer, the result is the common activation of YAP and TAZ (34). Previous studies have revealed that reorganization of the cell skeleton is a crucial factor affecting the phosphorylation levels of YAP and TAZ, and disrupting the structure of F-actin results in the activation of LAT51, which in turn inactivates YAP and TAZ (35-37). It is reported that ArgBP2 is a crucial protein involved in the formation of F-actin, and its upregulation inhibits the normal polymerization of actin (38,39). It has been demonstrated that MORC2 can inhibit the transcription of ArgBP2 via H2K27 trimethylation (40); therefore, MORC2 may be involved in maintaining the normal structure of F-actin and promoting the dephosphorylation of YAP/TAZ via the suppression of ArgBP2. This hypothesis will be tested in future investigations. When YAP and TAZ are activated, the proteins remain unphosphorylated, interacting with transcriptional factors TEA domain family member 1-4, translocating into the nucleus and activating the transcription of target genes, including connective tissue growth factor, insulin-like growth factor binding protein 3, integrin subunit β2, survivin, GLI family zinc finger 2 and AXL receptor tyrosine kinase, promoting cancer progression (34). In the present study, it was demonstrated that the dysregulation of MORC2 in liver cancer disrupted p53 and Hippo pathways, clarifying why p53 and Hippo pathways are aberrant in liver cancer.

The prognosis of patients with liver cancer is poor with high incidences of early metastasis and postoperative recurrence (22,41,42). Radical surgery, radiotherapy and liver transplantation are effective mainly for primary tumors, therefore, molecular-targeted therapy has been considered as a potential treatment tool (22,42). Clarifying the molecular mechanisms involved in the distant metastasis in liver cancer will enable promotion of the advancement of molecular-targeted therapies. In the present study, another novel finding...
was that MORC2 promoted the migration and invasion of cancer cells, which has not, to the best of our knowledge, been reported previously. It was also found that MORC2-knockdown sensitized liver cancer cells to chemotherapeutic drugs. These results indicated that MORC2-targeted therapy may be a potentially promising regimen to inhibit liver cancer metastasis and to improve the effect of chemotherapeutics for patients with advanced liver cancer and metastasis.

The present study had a number of limitations. It was found that MORC2-knockdown affected the proliferation and metastasis of liver cancer cells in vitro, however the present study did not investigate the effects of inhibiting MORC2 on the proliferation and lung metastasis of liver cancer cells in vivo. In addition, the study did not provide data on whether MORC2 modulated the p53, hippo and apoptotic pathways in vivo. The comprehensive underlying mechanism involved in MORC2 promoting liver cancer proliferation remains to be fully elucidated. Sánchez-Solana et al demonstrated that MORC2 promoted the activity of adenosine triphosphate citrate lyase (ACLY) by phosphorylation, and in turn activated acetyl-CoA carboxylase (ACC) and fatty acid synthase (FASN) (7). Of note, de novo lipogenesis is considered to be crucial in oncogenesis, and enhanced lipogenesis in cancer cells is reflected by improved activities of lipogenic enzymes, including ACLY, ACC and FASN (7,43-45). It is appropriate to suggest that MORC2 may promote cancer progression partly via this route. Additionally, by containing a CW zinc finger motif, which is predicted to be involved in DNA binding, MORC2 is considered to function as a transcriptional regulator (5). The high expression of MORC2 may alter the expression levels of certain crucial downstream tumor suppressors or oncogenes, in turn promoting the progression of cancer. These potential mechanisms require investigation and confirmation in the future. Additionally, it has been reported that the mutations of MORC2 may be involved in the development of Charcot-Marie-Tooth disease (46,47). The present study determined the mutation frequencies of MORC2 in tumor tissues using TCGA data, and it was demonstrated that the mutation frequencies of MORC2 in liver cancer and other types of cancer were low (data not shown). Therefore, it was hypothesized that mutation of MORC2 is not an important factor in tumor biology, which also requires validation in future investigations.

Acknowledgements

The authors would like to thank Professor Dongfeng Chen and Mr. Tao Wang (Daping Hospital, Chongqing, China) for providing access to the expression profile data of MORC2-overexpressing cells prior to publication.

Funding

This study was supported by the Natural Science Foundation of China (grant nos. 81172129, 81472798 and 81703030).

Availability of data and materials

The original expression profile or RNA sequencing data used in this study can be obtained from the following websites: TCGA database (http://www.cbioportal.org/) and GEO data-sets (GSE14520 and GSE22058) (https://www.ncbi.nlm.nih.gov/gds). The authors also declare that the datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors’ contributions

QD, HY, YG and FZ conceived and designed the experiments; QD, ZP and LW performed the experiments; QD, ZP, QG, LD, LW and MT wrote the paper.

Ethics approval and consent to participate

The inclusion of human samples was approved by the Ethics Review Board of the Second People’s Hospital of Guangdong Province (approval no. 2015-KYLL-023). All patients provided informed written consent prior to the investigation. All animal experiments were approved by the Ethics Review Board of the Second People’s Hospital of Guangdong Province (approval no. 2015-KYLL-063).

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin 61: 69-90, 2011.
2. Li DQ, Nair SS and Kumar R: The MORC family: New epigenetic regulators of transcription and DNA damage response. Epigenetics 8: 685-693, 2013.
3. Wang GL, Wang CY, Cai XZ, Chen W, Wang XH and Li F: Identification and expression analysis of a novel CW-type zinc finger protein MORC2 in cancer cells. Anat Rec (Hoboken) 293: 1002-1009, 2010.
4. Moissiard G, Cokus SJ, Cary J, Feng S, Billi AC, Stroud H, Husmann D, Zhan Y, Lajoie BR, McCord RP, et al: MORC family ATPases required for heterochromatin condensation and gene silencing. Science 336: 1448-1451, 2012.
5. Shao Y, Li Y, Zhang J, Liu D, Liu F, Zhao Y, Shen T and Li F: Involvement of histone deacetylation in MORC2-mediated down-regulation of carbonic anhydrase IX. Nucleic Acids Res 38: 2813-2824, 2010.
6. Li DQ, Nair SS, Ohshiro K, Kumar A, Nair VS, Pakala SB, Reddy SD, Gajula RP, Eswaran J, Aravind L, et al: MORC2 signaling integrates phosphorylation-dependent, ATPase-coupled chromatin remodeling during the DNA damage response. Cell Rep 2: 1657-1669, 2012.
7. Sánchez-Solana B, Li DQ and Kumar R: Cytosolic functions of MORC2 in lipogenesis and adipogenesis. Biochimica et Biophysica Acta (BBA)-. Mol Cell Res 1843: 316-326, 2014.
8. Chen LH, Kuo W-H, Tsai M-H, Chen P-C, Hsiao CK, Chuang EY, Chang LY, Hsieh FJ, Lai LC and Chang KJ: Identification of prognostic genes for recurrent risk prediction in triple negative breast cancer patients in Taiwan. PLoS One 6: e28222, 2011.
9. Liao XH, Zhang Y, Dong WJ, Shao ZM and Li DQ: Chromatin remodeling protein MORC2 promotes breast cancer invasion and metastasis through a PRD domain-mediated interaction with CTNNDD1. Oncotarget 8: 97941-97954, 2017.
10. Tong Y, Li Y, Gu H, Wang C, Liu F, Shao Y and Li F: HSF1, in association with MORC2, downregulates ArgBP2 via the PRC2 family in gastric cancer cells. Biochim Biophys Acta 1864: 1104-1114, 2018.
11. Zhang Q, Song Y, Liu T, Wang C, Zhang Q, Liu F, Cai X, Miao Z, Xu H, Xu H, et al: PAK1-mediated MORC2 phosphorylation promotes gastric tumorigenesis. Oncotarget 6: 9877-9886, 2015.
12. Zhang Q, Song Y, Chen W, Wang X, Miao Z, Cao L, Li F and Wang G: By recruiting HDAC1, MORC2 suppresses p21 Waf1/Cip1 in gastric cancer. Oncotarget 6: 16461-16470, 2015.
13. Roessler S, Jia HL, Budhu A, Forgues M, Ye QH, Lee JS, Thorgeirsson SS, Sun Z, Tang ZY, Qiu LX, et al: A unique metastasis gene signature enables prediction of tumor relapse in early-stage hepatocellular carcinoma patients. Cancer Res 70: 10202-10212, 2010.
14. Burchard J, Zhang C, Liu AM, Poon RT, Lee NP, Wong KF, Sham PC, Lam BY, Ferguson MD, Tokiwa G, et al: microRNA-122 as a regulator of mitochondrial metabolic gene network in hepatocellular carcinoma. Mol Syst Biol 6: 402, 2010.
15. Liu AM, Yao TJ, Wang W, Wong KF, Lee NP, Fan ST, Poon RT, Gao C and Luk JM: Circulating miR-15b and miR-130b in serum as potential markers for detecting hepatocellular carcinoma: A retrospective cohort study. BMJ Open 2: e000825, 2012.
16. Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, et al: Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal 6: p1l, 2013.
17. Cerami E, Gao J, Dogrusoz U, Gross B, Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, et al: The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov 2: 401-404, 2012.
18. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25: 402-408, 2001.
19. Ding Q, He K, Luo T, Deng Y, Wang H, Liu H, Zhang J, Chen K, Xiao J, Duan X, et al: SSRP1 Contributes to the Malignancy of Hepatocellular Carcinoma and Is Negatively Regulated by miR-497. Mol Ther 24: 903-914, 2016.
20. Hamahan D and Weinberg RA: Hallmarks of cancer: The next generation. Cell 144: 646-674, 2011.
21. Tao ZH, Wan JL, Zeng LY, Xie L, Sun HC, Qin LN, Wang L, Zhou J, Ren ZG, Li YX, et al: miR-612 suppresses the invasive-metastatic cascade in hepatocellular carcinoma. J Exp Med 210: 789-803, 2013.
22. Li P, Lin Y, Zhang Y, Zhu Z and Huo K: SSX2IP promotes metastasis and chemotherapeutic resistance of hepatocellular carcinoma. J Transl Med 11: 52, 2013.
23. Arakawa H: p53, apoptosis and axon-guidance molecules. Cell 122: 137-139, 2005.
24. Li P, Lin Y, Zhang Y, Huo K and Lin J: MicroRNA-362-5p promotes tumor growth and metastasis by targeting CYLD in hepatocellular carcinoma. Oncotarget 8: 16084-16098, 2017.
25. Zhang T, Wang J, Jiang H and Liu L: Hippo signaling in oval cells and hepatocarcinogenesis. Cancer Lett 302: 91-99, 2011.
26. Hong W and Guan KL: The Yap and Taz transcription co-activators: Key downstream effectors of the mammalian Hippo pathway. Semin Cell Dev Biol 23: 785-793, 2012.
27. Aragona M, Panciera T, Manfrin A, Giulieti F, Elvassore N, Dupont S and Piccolo S: A mechanical checkpoint controls multicellular growth through Yap/Taz regulation by actin-processing factors. Cell 154: 1047-1059, 2013.
28. Baes J, Kim SM and Lee H: The Hippo signaling pathway provides novel anti-cancer drug targets. Oncotarget 8: 16084-16098, 2017.
29. Zanconato F, Cordenonsi M and Piccolo S: Yap/Taz at the roots of cancer. Cancer Cell 29: 783-803, 2016.
30. Anekal PV, Yong J and Manser E: Arg kinase-binding protein 2 (ArgBP2) interaction with α-actinin and actin stress fibers inhibits cell migration. J Biol Chem 290: 2112-2125, 2015.
31. Cestra G, Toomre D, Chang S and De Camilli P: The Abl/Arg substrate ArgBP2/ArgBP2 coordinates the function of multiple regulatory mechanisms converging on the actin cytoskeleton. Proc Natl Acad Sci USA 102: 1731-1736, 2005.
32. Tong Y, Li Y, Gu H, Wang C, Liu F, Shao Y, Li J, Cao L and Li F: Microchondria protein 2, MORC2, downregulates the cytoskeleton adapter protein, ArgBP2, via histone methylation in gastric cancer cells. Biochem Biophys Res Commun 467: 821-827, 2015.
33. Ni F, Zhang H, Cui H, Wu Z, Chen L, Hu Z, Guo C, Liu Y, Chen Z, Wang X, et al: MicroRNA-362-5p promotes tumor growth and metastasis by targeting CYLD in hepatocellular carcinoma. Cancer Lett 356: 809-818, 2015.
34. Liu J, Han P, Li M, Yan W, Liu J, Liu J, He J, Tu W, Xia Y, Zhou Z, et al: The histidine-rich calcium binding protein (HRC) promotes tumor metastasis in hepatocellular carcinoma and is upregulated by SATB1. Oncotarget 6: 6811-6824, 2015.
35. Calvisi DF, Wang C, Ho C, Ludu S, Lee SA, Mattu S, Destefanis G, Delugó S, Zimmermann A, Ericsson J, et al: Increased lipogenesis, induced by AKT-mTORC1-RPS6 signaling, promotes development of human hepatocellular carcinoma. Gastroenterology 140: 1071-1083, 2011.
36. Wang C, Rajput S, Watabe K, Liao DF and Cao D: Acetyl-CoA carboxylase-α as a novel target for cancer therapy. Front Biosci (Schol Ed) 2: 515-526, 2010.
37. Wang Y, He D, Yang L, Wen B, Dai J, Zhang Q, Kang J, He W, Ding Q and He D: TRIM26 functions as a novel tumor suppressor of hepatocellular carcinoma and its downregulation contributes to worse prognosis. Biochem Biophys Res Commun 463: 458-465, 2015.
38. Laššuthová P, Šafráková D, Krůtová M, Mazanec R, Züchner S, Gonzalez MA and Seeman P: Severe axonal Charcot-Marie-Tooth disease with proximal weakness caused by de novo mutation in the MORC2 gene. Brain 139: e26, 2016.
39. Zhao X, Li X, Hu Z, Liu L, Xie Y, Tian T, Man J, Wang J, Zi X, Xia K, et al: MORC2 mutations in a cohort of Chinese patients with Charcot-Marie-Tooth disease type 2. Brain 139: e56, 2016.